Gland Pharma Q4 FY26 Results: PAT Rs 367 Cr, Revenue Rs 1,743 Crore

Gland Pharma Q4 FY26 results were declared on May 15, 2026, at the board of directors meeting. Gland Pharma reported PAT of Rs 367 crore for the quarter ended March 31, 2026, up 96.3% YoY from Rs 187 crore in Q4 FY25, on revenue of Rs 1,743 crore. Gland Pharma is a pharmaceutical formulations and APIs company. Investors tracking Gland Pharma Q4 FY26 will find complete financial analysis, segment performance, and FY27 outlook in this article.

Click Here – Get Free Investment Predictions

Gland Pharma Q4 FY26 Financial Highlights

Gland Pharma Q4 FY26 Performance Analysis

Gland Pharma Q4 FY26 results reflect the company’s operational performance during the January to March 2026 quarter. Gland Pharma operates in the pharmaceutical formulations and APIs space, a sector that has seen strong demand tailwinds in FY26 driven by domestic consumption growth, government capex, and India’s infrastructure buildout. The Q4 results cap the full FY26 year and set the baseline for FY27 guidance.

The quarter’s profitability improvement reflects better operating leverage, pricing discipline, and cost management. Investors tracking Gland Pharma Q4 FY26 will monitor FY27 revenue visibility and management commentary on margin sustainability. Track Gland Pharma on the Univest Screener for live data and analyst ratings.

Key Business Factors for Gland Pharma Q4 FY26

Sectoral Demand and Revenue Momentum

Gland revenue of Rs 1,743 crore reflects the company’s ability to execute in a competitive pharmaceutical formulations and APIs environment. Q4 is typically the strongest quarter for most Indian companies as year-end government spending, project completions, and festival-driven demand peak. The revenue trajectory for FY27 will be determined by order book conversions, new contract wins, and demand visibility from key customers.

Margin and Profitability Outlook

The company PAT of Rs 367.0 crore reflects profitable operations with improving margins across the business. EBITDA margin trends and operating leverage will be key metrics to watch as FY27 guidance is finalised.

FY27 Guidance and Business Outlook

Following the firm results, management commentary on FY27 revenue guidance, capital expenditure plans, dividend policy, and strategic priorities will be the key near-term catalysts for the stock. India’s robust GDP growth of 6.5%+ and the government’s sustained infrastructure and consumption push create a positive macro backdrop for FY27 across most sectors. Monitor Gland Pharma financials in real time on the Univest Screener.

Check the Univest Screener for live data

Download the Univest iOS App or Univest Android App to track live prices and SEBI-registered analyst research.

Frequently Asked Questions on Gland

What is the company PAT?

Ans. Gland reported PAT of Rs 367 crore up 96.3% YoY from Rs 187 crore in Q4 FY25. Results were declared on May 15, 2026. Full details are available from NSE/BSE regulatory filings. Verify all numbers before investing.

What is the company revenue?

Ans. The firm’s revenue from operations was Rs 1,743 crore for the quarter ended March 31, 2026. Track real-time financials on the Univest Screener.

When were Gland results announced?

Ans. The company results were announced on May 15, 2026, at the board of directors meeting approving audited financial statements for Q4 and the full year ended March 31, 2026.

What sector does Gland Pharma operate in?

Ans. Gland Pharma operates in the pharmaceutical formulations and APIs sector. Download the Univest iOS App or Univest Android App to track Gland Pharma and get SEBI-registered research.

Is Gland Pharma a good investment after Q4 FY26?

Ans. Investment decisions should be based on comprehensive analysis of fundamentals, sector dynamics, valuation, and individual risk appetite. This article does not constitute investment advice. Consult a SEBI-registered financial advisor before investing. This content is for educational purposes only.

Investments in securities are subject to market risk. This content is for educational purposes only and does not constitute investment advice.